Edition:
United States

Novan Inc (NOVN.OQ)

NOVN.OQ on NASDAQ Stock Exchange Global Market

2.51USD
19 Oct 2018
Change (% chg)

$-0.08 (-2.91%)
Prev Close
$2.58
Open
$2.58
Day's High
$2.58
Day's Low
$2.51
Volume
2,306
Avg. Vol
9,442
52-wk High
$6.64
52-wk Low
$2.27

Summary

Name Age Since Current Position

Robert Ingram

75 2011 Independent Chairman of the Board

Nathan Stasko

36 2017 President, Chief Scientific Officer, Director

G Kelly Martin

58 2017 Interim Chief Executive Officer, Director

Jeff Hunter

2018 Chief Business Officer, Interim Chief Financial Officer and Principal Financial Officer

Stanley Hollenbach

2017 Senior Vice President - Research and Development

Andrew Novak

36 2018 Vice President, Chief Accounting Officer and Principal Accounting Officer

Paula Stafford

2017 Chief Development Officer, Director

Brian Johnson

50 2015 Chief Commercial Officer

Machelle Sanders

2017 Director

Eugene Sun

2018 Director

W. Geer

62 2015 Independent Director

Robert Keegan

70 2016 Independent Director

John Palmour

54 2010 Independent Director

Biographies

Name Description

Robert Ingram

Mr. Robert A. Ingram is a Independent Chairman of the Board of the Company. He is the Chairman of our board of directors and has served as a member of our board of directors since 2011. Since 2007, he has been a General Partner at Hatteras Venture Advisors III, LLC, a venture capital firm. Mr. Ingram currently serves on the board of directors of Valeant Pharmaceuticals International, Cree, Inc., Edwards Lifesciences Corporation, Regeneron Pharmaceuticals, Inc. and PhaseBio Pharmaceuticals, Inc.

Nathan Stasko

Dr. Nathan Stasko, Ph.D., is President, Chief Scientific Officer, Director of the Company. He is one of our co-founders and has served as our President, Chief Executive Officer and a member of our board of directors since 2006.

G Kelly Martin

Mr. G. Kelly Martin is Interim Chief Executive Officer, Director of the Company. He has served as a member of our board of directors since 2015. Since August 2015, Mr. Martin has served as the Chief Executive Officer of Malin Corporation PLC, a biotechnology company. Previously, he served as Chief Executive Officer of Elan Corporation PLC, a biotechnology company, from February 2003 to December 2013, and he founded Brandon Point Industries, a life sciences company, in January 2014, where he currently serves as director. Mr. Martin also currently serves on the board of directors of Viamet Pharmaceuticals Holdings, LLC.

Jeff Hunter

Mr. Jeff N. Hunter is Chief Business Officer, Interim Chief Financial Officer and Principal Financial Officer of the Company. Mr. Hunter has served as our Vice President of Technical Operations since 2006.

Stanley Hollenbach

Mr. Stanley Hollenbach is Senior Vice President - Research and Development of the company. Prior to his promotion, Mr. Hollenbach led the design and execution of all pharmacology and toxicology testing for the Company as Vice President of Research and Nonclinical Development since joining Novan in March 2014. Mr. Hollenbach has more than 25 years of experience in the biotechnology industry, including lengthy terms of service at Genentech, COR Therapeutics, which was acquired by Millennium Pharmaceuticals, and Portola Pharmaceuticals. Most recently during his tenure at Portola, he focused primarily on platelet and fibrin mediated thrombosis, leading the preclinical development of orally bioavailable antiplatelet P2Y12 antagonists and the factor Xa inhibitors andexanet alpha and betrixaban. Mr. Hollenbach earned a Bachelor of Science in Microbiology and Bachelor of Arts in Chemistry from The University of North Carolina at Charlotte and a Juris Doctorate from the Peninsula University College of Law.

Andrew Novak

Mr. Andrew J. Novak is Vice President, Chief Accounting Officer and Principal Accounting Officer of the company. He has served as the Company’s Director of Financial Reporting and Analysis since June 2016 and Senior Director of Financial Reporting and Analysis since March 2018. From June 2014 until March 2016, Mr. Novak served as Director of Financial and SEC Reporting for Scynexis, Inc., a biotechnology company. Prior to joining Scynexis, Inc., Mr. Novak served as an Audit Manager at Deloitte & Touche from September 2005 to October 2012 and as a Technical Manager, Accounting & Audit Publications for the American Institute of Certified Public Accountants from October 2012 to June 2014. Mr. Novak is a certified public accountant and holds both a Bachelor of Science in Business Administration, Finance and a Master of Science in Accountancy from the University of North Carolina at Wilmington.

Paula Stafford

Ms. Paula Brown Stafford is Chief Development Officer, Director of the company. Most recently, Ms. Stafford served as president of clinical development at Quintiles (now QuintilesIMS), where she was responsible for all Phase I-IV clinical development operations globally, reaching $3 billion in annual revenue. During her time at Quintiles, Ms. Stafford was also a member of the Quintiles executive committee for more than five years. In addition to her new role at Novan, Ms. Stafford will continue to participate in other professional activities, including serving as a director at Health Decisions, Inc. and adjunct professor in Public Health Leadership at the Gillings School of Global Public Health at The University of North Carolina at Chapel Hill, and will also maintain her third-party consulting business. Ms. Stafford was a 2011 recipient of the Triangle Business Journal’s Women in Business award and named as one of the 10 top women in biotech by FierceBiotech in 2012. She holds a Bachelor of Science and a Masters in Public Health, both from The University of North Carolina at Chapel Hill, with her specialization in Biostatistics.

Brian Johnson

Mr. Brian Johnson is a Chief Commercial Officer of the Company. He has served as our Chief Commercial Officer since September 2015. Prior to joining Novan, Mr. Johnson worked at Galderma Laboratories, L.P. from 2003 to 2014, and most recently served as Vice President of Prescription Marketing and Chief Digital Officer. He also currently serves as principal and sole advisor of Two Hearts Group, LLC, a consulting company focused on drug development companies.

Machelle Sanders

Eugene Sun

W. Geer

Mr. W. Kent Geer is a Independent Director of the Company. He has served as a member of our board of directors since 2015. Mr. Geer was an audit partner with Ernst & Young LLP from 1989 to 2011. Beginning in 2012, Mr. Geer served as the Chairman of the board of directors of PowerSecure International, Inc. until the successful sale of the company in May 2016.

Robert Keegan

Mr. Robert J. Keegan is a Independent Director of the Company. He has served as a member of our board of directors since 2016. Mr. Keegan held the roles of Chief Executive Officer and Chairman of the board of directors of Goodyear Tire and Rubber Co. from 2000 to 2010. Most recently, he was an operating partner of the San Francisco-based private equity firm Friedman, Fleischer & Lowe. From 1972 to 2000, Mr. Keegan held various marketing, financial and managerial posts at Eastman Kodak, except for a two-year period from 1995 to 1997 when he worked as an Executive Vice President of the Avery Dennison Corporation. Mr. Keegan is Chairman of the Board of Loparex, Inc., serves on the boards of the Xerox Corporation.

John Palmour

Dr. John W. Palmour, Ph.D., is a Independent Director of the Company. He has served as a member of our board of directors since 2010. Since 1987, Dr. Palmour has worked at Cree, Inc., a company he co-founded and for which he currently serves as a Vice President and the Chief Technology Officer, Power & Radio Frequency.